Teladoc Health’s (TDOC) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Teladoc Health (NYSE:TDOC) in a research report sent to investors on Friday morning, Benzinga reports.

A number of other analysts also recently weighed in on the stock. Truist Financial decreased their price target on shares of Teladoc Health from $23.00 to $17.00 and set a hold rating for the company in a research report on Wednesday, March 6th. Leerink Partnrs reissued a market perform rating on shares of Teladoc Health in a research report on Monday, February 26th. SVB Leerink initiated coverage on shares of Teladoc Health in a research report on Monday, February 26th. They set a market perform rating and a $17.00 price target for the company. Royal Bank of Canada decreased their price target on shares of Teladoc Health from $30.00 to $25.00 and set an outperform rating for the company in a research report on Wednesday, February 21st. Finally, Cantor Fitzgerald initiated coverage on shares of Teladoc Health in a research report on Thursday, February 29th. They set an overweight rating and a $22.00 price target for the company. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $19.00.

Teladoc Health Stock Down 2.4 %

TDOC opened at $13.01 on Friday. The firm has a 50 day moving average price of $14.85 and a 200 day moving average price of $17.71. The company has a market cap of $2.20 billion, a PE ratio of -9.23 and a beta of 0.94. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. During the same period last year, the company posted ($0.37) EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Sell-side analysts expect that Teladoc Health will post -1.06 earnings per share for the current year.

Insider Activity

In other news, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares of the company’s stock, valued at $1,097,537.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Arnnon Geshuri sold 7,500 shares of Teladoc Health stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $15.06, for a total transaction of $112,950.00. Following the transaction, the insider now directly owns 38,470 shares of the company’s stock, valued at $579,358.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares in the company, valued at $1,097,537.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 135,441 shares of company stock valued at $2,038,251. Company insiders own 1.63% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC increased its stake in Teladoc Health by 4.5% in the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock worth $457,389,000 after purchasing an additional 912,692 shares in the last quarter. Vanguard Group Inc. increased its stake in Teladoc Health by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after purchasing an additional 1,855,480 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Teladoc Health by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after acquiring an additional 767,999 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Teladoc Health by 6.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,654,116 shares of the health services provider’s stock worth $35,646,000 after acquiring an additional 104,531 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Teladoc Health by 9.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 658,435 shares of the health services provider’s stock valued at $12,240,000 after acquiring an additional 57,989 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.